HYCAMTIN for injection is a topoisomerase inhibitor indicated for treatment of: •. Patients with metastatic ovarian cancer after disease progression on or.
HYCAMTIN 1 mg powder for concentrate for solution for infusion The contents of HYCAMTIN 4 mg vials must be reconstituted with 4 ml water for injections.
WARNING. 7. HYCAMTIN (topotecan hydrochloride) for Injection should be administered under the. 8 supervision of a physician experienced in the use of cancer
See full prescribing information for HYCAMTIN FOR INJECTION. HYCAMTIN® (topotecan) for injection for intravenous use. Initial U.S. Approval: 1996. WARNING:
29 Aug 2019 Combination therapy (cervical carcinoma) - It is recommended that topotecan in combination with cisplatin for the treatment of cervical cancer ...
Topotecan Injection is indicated for the treatment of chemotherapy-sensitive small cell lung cancer (SCLC) after failure of first-line chemotherapy.
Topotecan Hydrochloride for Injection. HYCAMTIN® HYCAMTIN in combination with cisplatin is indicated for the treatment of patients with.
Hycamtin® 1 mg powder for concentrate for solution for infusion Mild pain and inflammation at the site of injection. •. Itchy rash (or hives).
7 Jan 2019 Hycamtin 4 mg powder for injection: 2 vials per 7 days. B. Max Units (per dose and over time) [Medical Benefit]:. Cervical Cancer.
3 Oct 2012 Topotecan Injection. Generic Name. Topotecan hydrochloride. Reference Listed Drug. Hycamtin. ®. NDA 20671. Proposed Indication.
HYCAMTIN®for injection as a single agent is indicated for the treatment ofpatients with metastatic ovarian cancerafter disease progression onor after initial or subsequentchemotherapy 1 2 Small Cell Lung Cancer HYCAMTIN for injection as a single agent is indicated for the treatment of patients with small cell lung
HYCAMTIN for injection is a cytotoxic drug Follow applicable handling and disposal procedures 1 3 DOSAGE FORMS AND STRENGTHS For injection: 4 mg (free base) of topotecan as a light yellow to
HYCAMTIN for injection as a single agent is indicated for the treatment of patients with small cell lung cancer (SCLC) with platinum-sensitive disease who progressed at least 60 days after
HYCAMTIN® (topotecan hydrochloride) for Injection Initial U S Approval: 1996 WARNING: BONE MARROW SUPPRESSION See full prescribing information for complete boxed warning Do not give HYCAMTIN
HYCAMTIN (topotecan hydrochloride) is a semi-synthetic derivative of camptothecin and is an anti-tumor drug with topoisomerase I-inhibitory activity HYCAMTIN for Injection is supplied as a sterile
HYCAMTIN® capsules are indicated for the treatment of relapsed small cell lung cancer (SCLC) in patients with a prior complete or partial response and who are at least 45 days from the end of first-line chemotherapy 2 DOSAGE AND ADMINISTRATION 2 1 Recommended Dosage
Hycamtin (topotecan) is a semi-synthetic derivative of camptothecin and is an anti-tumor drug with topoisomerase I-inhibitory activity Topoisomerase I relieves torsional strain in DNA by inducing reversible single-strand breaks Topotecan binds to the topoisomerase I- DNA complex and prevents re-ligation of these single-strand breaks
Product identifier HYCAMTIN INJECTABLE Other means of identification Not available Synonym(s) HYCAMTIN INFUSION 1 MG/3 ML * HYCAMTIN INJECTION 1 MG/3 ML * HYCAMTIN INJECTION 4 MG/5 ML * HYCAMTIN INJECTION (CONTAINING 10 TOPOTECAN) * TOPOTECAN FORMULATED PRODUCT Recommended use Medicinal Product
Hycamtin® The proposed drug product is in the same dosage form (i e injectable solution) containing the same active ingredient at the same concentration after reconstitution as the RLD and is
HYCAMTIN capsules are indicated for the treatment of relapsed small cell lung cancer in patients with a prior complete or partial response and who are at least 45 days from the end of first-line chemotherapy 2 DOSAGE AND ADMINISTRATION 2 1 Recommended Dosing The recommended dose of HYCAMTIN capsules is 2 3 mg/m 2 /day orally once daily for 5
Hycamtin for injection is indicated: • As a single agent for the treatment of patients with metastatic carcinoma of the ovary after disease progression on or after initial or subsequent chemotherapy • As a single agent for the treatment of patients with small cell lung cancer with platinum-